-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Attrition Analysis
Government Commitment to the Global Action Against Dementia (WDC / Department of Health)
Summary The Department of Health has responded to Raj Long’s Finding a path for a cure for dementia: an independent report into an integrated approach to dementia drug development report, with a Strategy Report and an open letter. There is … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO)
|
Tagged $100m Dementia Discovery Fund, Academia-Industry Partnerships, Academic Research, Accelerated Access Review, AIFA: Italian Medicines Agency, Alzheimer's Association, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP), Composite End Points, Continuity Plans (WDC and GAAD Agenda), Council for International Organizations of Medical Sciences (CIOMS), Cross-Sector Partnerships, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Integrated Development Initiative, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, EMA: European Medicines Agency, EU Joint Programme on Neurodegenerative Disease Research (JPND), EU’s Neurodegenerative Disease Research Joint Programme (JPND), European Medicines Agency, European Medicines Agency (EMA), European Prevention of Alzheimer's Dementia Consortium (EPAD), First Global Ministerial Conference on Global Action Against Dementia, Foundation Plan Alzheimer’s, GAAD: Global Action Against Dementia, George Freeman MP: Former Life Sciences Minister, Gill Ayling: Deputy Director of Global Action Against Dementia (Department of Health), Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Alzheimer’s Leadership Series (GoALS), Global Alzheimer’s Platform, Global CEO initiative (CEOi) on Alzheimer’s Disease, Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Observatory on Dementia (WHO), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Integrated Development Advisory Group, International Coalition of Medicines Regulatory Agencies, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Pharmaceutical Regulatory Forum, International Programmes, Italian Medicines Agency, Jane Ellison MP: Parliamentary Under Secretary for Public Health, Joint Programme on Neurodegenerative Disease Research (JPND), JPND: Joint Programme on Neurodegenerative Disease Research, Medical Research Council (MRC), Modelling and Extrapolation, Multilateral Cooperation, National Institute for Health Research (NIHR), National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, NeuroMap, New York Academy of Sciences (NYAS), Observatory on Dementia (WHO), OLS Accelerated Access Review, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Risk Benefit Balance, Swiss Medic, University of Newcastle, US National Institute on Aging, WDC: World Dementia Council, WHO Observatory on Dementia, WHO's Global Observatory on Dementia, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Dementia: the R&D Landscape: Mapping UK Dementia Research and Workforce Capacity (RAND Europe / WDC / OHE)
Summary The Alzheimer’s Society commissioned RAND Europe to analyse the UK’s dementia research “landscape” and workforce capacity. The following report relates to the state of funding and capacity in dementia research. It covers: An audit of the types of research … Continue reading →
Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, End of Life Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, NIHR, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Systematic Reviews, UK, Universal Interest
|
Tagged Active Dementia Researchers: By Sector etc., Alzheimer’s Research UK’s Preparatory Clinical Research Fellowships, Alzheimer’s Society Clinical and Healthcare Professionals Training Fellowships, Amyloid Fibril Formation, Amyloid Hypothesis, Attrition Analysis, Benchmarking, Bibliometric and Citation Analysis of UK Dementia Research, Bibliometric Data, Bibliometric Indicators: Average of Relative Citations (ARCs), Bibliometric Indicators: Average of Relative Impact Factors (ARIFs) - Journals Specialisation Index (SI), Bibliometric Indicators: Growth Ratio (GR), Bibliometric Indicators: Highly Cited Publications (HCPs), Bibliometric Indicators: International Collaboration, Bibliometric Indicators: Number of Papers, Bibliometric Indicators: Transdisciplinarity, Brain Imaging, Centres of Excellence Network in Neurodegeneration (CoEN), Clinical and Technical Expert Group (CTEG), Collaborations for Leadership in Applied Health Research and Care (CLAHRCs), Collaborations for Leadership in Applied Health Research and Care (CLAHRCs)'s Research Capacity in Dementia Care Programme, Dementia Integrated Development Initiative's Clinical and Technical Expert Group (CTEG), Dementia Policy: Research, Dementia R&D Costs: Lower Success Rates and Longer Development Times, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Leaders Programme, Dementia Research Priorities, Dementia Research Workforce Pipeline, Dementia Research: UK Impact, Dementia Researchers Workforce Pipeline (Dementia Research), Dementia: the R&D Landscape, Dementia: The R&D Landscape (OHE 2015), Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Department of Health’s Integrated Development Initiative, Disease Modifying Versus Symptom Modifying Treatments (Widespread Mis-Classification in Drugs Development Pipeline), DPUK: Dementias Platform UK, Enabling Dementia Research Careers, Epidemiology, EThOS Database, EU Joint Programme in Neurodegenerative Disease (JPND), EU Joint Programme on Neurodegenerative Disease Research (JPND), EU’s Neurodegenerative Disease Research Joint Programme (JPND), Genetics, Global Context, Imperial College London, Integrated Development, JPND, JPND: Joint Programme on Neurodegenerative Disease Research, Lewy Body Dementia, Mapping of UK Dementia Research and Workforce Capacity, Most Prolific Dementia Researchers: By Field, Most Prolific Dementia Researchers: By Subfield, Office for Health Economics, Office of Health Economics (OHE), OHE: Office of Health Economics, PhD Tracing (Dementia-Related), Pipeline Analysis, Pipeline Databases: European Union Clinical Trials Register, Pipeline Databases: IMS LifeCycle R&D Focus, Pipeline Databases: U.S. National Institutes of Health Database, Psychosocial Interventions, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, RAND Europe, RAND Europe’s Dementia Research Landscape and Workforce Capacity Report (2015), Reasons for Project Discontinuation, Reasons for Successes and Failures of Dementia Treatments, Research Capacity in Dementia Care Programme, Researcher Retention in Dementia Research, Retention of UK Dementia Research Graduates in Dementia Research, Science Metrix, Training and Capacity-Building, UK Dementia Research Topics and Subtopics: Alzheimer’s Disease, UK Dementia Research Topics and Subtopics: Binswanger’s Disease, UK Dementia Research Topics and Subtopics: Cadasil, UK Dementia Research Topics and Subtopics: Early Onset Dementia, UK Dementia Research Topics and Subtopics: Familial Dementia, UK Dementia Research Topics and Subtopics: Frontotemporal Dementia, UK Dementia Research Topics and Subtopics: Late Onset Dementia, UK Dementia Research Topics and Subtopics: Lewy Body Dementia, UK Dementia Research Topics and Subtopics: Logopenic Primary Aphasia, UK Dementia Research Topics and Subtopics: Mild Cognitive Impairment, UK Dementia Research Topics and Subtopics: Other classifications (Syndromes), UK Dementia Research Topics and Subtopics: Pick’s Disease, UK Dementia Research Topics and Subtopics: Post-Stroke Dementia, UK Dementia Research Topics and Subtopics: Posterior Cortical Atrophy, UK Dementia Research Topics and Subtopics: Primary Progressive Aphasia, UK Dementia Research Topics and Subtopics: Primary Progressive Nonfluent Aphasia, UK Dementia Research Topics and Subtopics: Small Vessel Disease, UK Dementia Research Topics and Subtopics: Subcortical Dementia, UK Dementia Research Topics and Subtopics: Subcortical Ischemic Vascular Dementia, UK Dementia Research Topics and Subtopics: Vascular Cognitive Impairment, UK Dementia Research Topics and Subtopics: Vascular Dementia, UK Dementia Research Workforce, UK Dementia Research: Challenges Bottlenecks and Opportunities, UK Dementia Research: Global Perspective, UK Dementia-Related Research, UK Dementia-Related Research Subfields: Biochemistry and Molecular Biology, UK Dementia-Related Research Subfields: Biophysics, UK Dementia-Related Research Subfields: Cardiovascular System and Hematology, UK Dementia-Related Research Subfields: Clinical Psychology, UK Dementia-Related Research Subfields: Developmental Biology, UK Dementia-Related Research Subfields: Endocrinology and Metabolism, UK Dementia-Related Research Subfields: Epidemiology, UK Dementia-Related Research Subfields: Experimental Psychology, UK Dementia-Related Research Subfields: General and Internal Medicine, UK Dementia-Related Research Subfields: General Clinical Medicine, UK Dementia-Related Research Subfields: General Science and Technology, UK Dementia-Related Research Subfields: Genetics and Heredity, UK Dementia-Related Research Subfields: Geriatrics, UK Dementia-Related Research Subfields: Gerontology, UK Dementia-Related Research Subfields: Health Policy and Services, UK Dementia-Related Research Subfields: Immunology, UK Dementia-Related Research Subfields: Medicinal and Biomolecular Chemistry, UK Dementia-Related Research Subfields: Microbiology, UK Dementia-Related Research Subfields: Neurology and Neurosurgery, UK Dementia-Related Research Subfields: Nuclear Medicine and Medical Imaging, UK Dementia-Related Research Subfields: Nursing, UK Dementia-Related Research Subfields: Nutrition and Dietetics, UK Dementia-Related Research Subfields: Oncology and Carcinogenesis, UK Dementia-Related Research Subfields: Organic Chemistry, UK Dementia-Related Research Subfields: Pathology, UK Dementia-Related Research Subfields: Pharmacology and Pharmacy, UK Dementia-Related Research Subfields: Psychiatry, UK Dementia-Related Research Subfields: Public Health, UK Dementia-Related Research Subfields: Rehabilitation, UK Dementia-Related Research Subfields: Virology, UK Spending on Dementia Research, WDC: World Dementia Council, Workforce, Workforce Development, Workforce Issues, Workforce Planning, World Dementia Council
|
Leave a comment
Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)
Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)
Summary The Medicines and Healthcare Products Regulatory Agency (MHRA) took part in an international workshop with other regulators, and has released a statement of intent about how to support the development of drugs for dementia. This work is in support … Continue reading →
Posted in Department of Health, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, World Health Organization (WHO)
|
Tagged Accelerating Alzheimer's Research and Drug Development, Attrition Analysis, Bill and Melinda Gates Foundation, Clinical Trial Efficiency, Composite End Points: Development of Standardised and Validated Endpoint Components, Coordinated Regulatory Action, Danish Health and Medicines Authority, Dementia Research, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Regulation, Drug-Development Pipeline, European Medicines Agency, Expediting Regulatory Approval Procedures: Balancing Benefits and Risks, Federal Institute for Drugs and Medical Devices, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G7 Global Dementia Summit, G8 Dementia Summit, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Global Regulatory Efficiency and Consistency, Health Canada, Incentives, Incentives for Drug Development, International Federation of Pharmaceutical Manufacturers and Associations, Italian Medicines Agency, Market Failure (Dementia Research and Drug Development), Medicines and Healthcare Products Regulatory Agency, Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines Evaluation Board, Multilateral Cooperation: Reducing Unnecessary Testing Replication and Methodology Testing, Office for Life Sciences, Pharmaceutical and Medicines Devices Agency (Japan), Pharmaceutical Regulators, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulation, Regulators, Regulatory Barriers, Regulatory Research Dementia Workshop, Regulatory System, Removing Regulatory Barriers, Research and Innovation, Resource and Incentives, Swissmedic, Translational Research, US Food and Drug Administration, WDC: World Dementia Council, WHO: World Health Organization, World Dementia Council
|
Leave a comment
